Clinical features and outcomes of Myasthenia Gravis associated with COVID-19 vaccines: A systematic review and pooled analysis.
Amir Hossein TayebiParham SamimisedehElmira Jafari AfsharAryan AyatiElaheh GhalehnoviLaleh ForoutaniNahid Abbasi KhoshsiratHadith RastadPublished in: Medicine (2023)
MG cases after the COVID-19 vaccine are more likely to occur among males and adults older than 50 years. Our pooled cohort data suggest MG symptoms appear within 2 weeks after receiving the vaccine. The presenting symptoms in MG cases associated with COVID-19 vaccine are possibly similar to non-vaccination related MGs. Most patients are expected to experience partial/complete improvement within 1 month.
Keyphrases
- coronavirus disease
- sars cov
- myasthenia gravis
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- respiratory syndrome coronavirus
- peritoneal dialysis
- electronic health record
- sleep quality
- randomized controlled trial
- skeletal muscle
- depressive symptoms
- clinical trial
- patient reported outcomes
- adipose tissue
- deep learning
- case report
- metabolic syndrome
- insulin resistance
- preterm birth
- community dwelling
- gestational age